BNY Mellon Selected as Depositary by Takeda Pharmaceutical for its Sponsored OTC-Traded Depositary Receipt Program

Monday, May 10, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+



NEW YORK, May 10 BNY Mellon, the global leader in asset management and securities servicing, has been appointed by Takeda Pharmaceutical Company Limited (Takeda) as the depositary bank for its sponsored American depositary receipt (ADR) program. Each Takeda ADR represents one-half of a common share and trades on the over-the-counter (OTC) market under the symbol TKPYY. Takeda's common shares trade on the Tokyo Stock Exchange as well as four other exchanges in Japan under the code "4502." Previously, Takeda traded as an unsponsored ADR program serviced by multiple depositaries.

Takeda is a research-based global pharmaceutical company engaged in the production and sale of prescription drugs and over-the-counter drugs. Takeda maintains research centers in Japan, the U.S., Singapore and the UK with products available in nearly 90 countries worldwide.

"Takeda's continued expansion into Europe and the Americas underscores its growth capabilities and commitment to building a worldwide brand," said Michael Cole-Fontayn, chief executive officer of BNY Mellon's Depositary Receipts business. "By sponsoring their OTC-traded ADR program, Takeda will be better-positioned to take advantage of its global brand recognition and growth initiatives."

BNY Mellon acts as depositary for more than 2,100 American and global depositary receipt programs, acting in partnership with leading companies from 67 countries. With an unrivaled commitment to helping securities issuers succeed in the world's rapidly evolving financial markets, the company delivers the industry's most comprehensive suite of integrated depositary receipt, corporate trust and stock transfer services. Learn more at www.bnymellon.com/dr.

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK). BNY Mellon is a global financial services company focused on helping clients manage and service their financial assets, operating in 34 countries and serving more than 100 markets. BNY Mellon is a leading provider of financial services for institutions, corporations and high-net-worth individuals, providing superior asset management and wealth management, asset servicing, issuer services, clearing services and treasury services through a worldwide client-focused team. It has $22.4 trillion in assets under custody and administration, $1.1 trillion in assets under management, services $11.8 trillion in outstanding debt and processes global payments averaging $1.5 trillion per day. Learn more at www.bnymellon.com.

This release is for informational purposes only. BNY Mellon provides no advice nor recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. Depositary Receipts: Not FDIC, State or Federal Agency Insured; May Lose Value; No Bank, State or Federal Agency Guarantee.

SOURCE BNY Mellon


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook